Metacrine, Inc. (MTCR) |
|
0.4523 0.062 (15.97%)
|
05-16 07:36 |
|
Open: |
0.418 |
Pre. Close: |
0.39 |
|
High:
|
0.466 |
Low:
|
0.41 |
|
Volume:
|
1,420,180 |
Market Cap:
|
19(M) |
|
|
|
|
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.47 - 0.47 |
0.47 - 0.47 |
|
Low:
|
0.41 - 0.41 |
0.41 - 0.41 |
|
Close:
|
0.45 - 0.45 |
0.45 - 0.46 |
|
Technical analysis |
as of: 2022-05-13 4:39:58 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.63 One year: 0.77 |
| Support: |
Support1: 0.34 Support2: 0.29 |
| Resistance: |
Resistance1: 0.54 Resistance2: 0.66 |
| Pivot: |
0.43  |
| Moving Average: |
MA(5): 0.39 MA(20): 0.45
MA(100): 0.53 MA(250): 1.91 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 33.7 %D(3): 21.3 |
| RSI: |
RSI(14): 47.7 |
| 52-week: |
High: 4.84 Low: 0.34 |
| Average Vol(K): |
3-Month: 1,699 (K) 10-Days: 837 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MTCR ] has closed below upper band by 40.9%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Mon, 16 May 2022
What We Must Do to Help Ukraine Win - The Dispatch
Sun, 15 May 2022
Metacrine, Inc. (NASDAQ:MTCR) Sees Large Decline in Short Interest - Defense World
Thu, 12 May 2022
IAF test-fires extended-range BrahMos from Sukhoi fighter - The Tribune India
Fri, 29 Apr 2022
Building Alliances and Competing with China - Air Force Magazine
Wed, 20 Apr 2022
IAF test fires BrahMos missile from Su-30 MKI with ‘pinpoint accuracy’ on a naval target - Frontline
Wed, 20 Apr 2022
Metacrine, Inc. (NASDAQ:MTCR) CEO Preston Klassen Sells 44748 Shares - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
18.8 (%) |
|
% Held by Institutions
|
29.3 (%) |
|
Shares Short
|
846 (K) |
|
Shares Short P.Month
|
788 (K) |
Stock Financials |
|
EPS
|
-2.27 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.77 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-40.6 |
|
Return on Equity (ttm)
|
-82 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.64 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.39 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-47 (M) |
|
Levered Free Cash Flow
|
-26 (M) |
Stock Valuations |
|
PE Ratio
|
-0.2 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.25 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.41 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
